Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

NCT05460195 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
Minimal Residual Disease
Immunotherapy
Anti-angiogenesis

Interventions

DRUG: sintilimab combined with anlotinib
DRUG: sintilimab monotherapy

Sponsor

Shanghai Chest Hospital